ReviewAnnual review of pathology2010
Mutational heterogeneity in human cancers: origin and consequences.
Review in Annual review of pathology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 111 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
111 citing papers in PubMed, 247 citations in OpenAlex.
- Mini-Galaxy: Rethinking Complex Human Diseases Through the Lens of Systems Biology and Multilayered AI Network Perspectives.International journal of molecular sciences · 2026Review
- IgE based therapeutics are an emerging modality in cancer treatment.Discover oncology · 2025Review
- Tumor heterogeneity in retinoblastoma: a literature review.Cancer metastasis reviews · 2025Review
- CAR T-cell therapy in cancer: Integrating nursing perspectives for enhanced patient care.Asia-Pacific journal of oncology nursing · 2024Review
- Review
- Y-Box Binding Protein 1: Unraveling the Multifaceted Role in Cancer Development and Therapeutic Potential.International journal of molecular sciences · 2024Review
- Review
- A Clonal Evolution Simulator for Planning Somatic Evolution Studies.Journal of computational biology : a journal of computational molecular cell biology · 2023Article
- Biochemistry-Not Oncogenes-May Demystify and Defeat Cancer.Oncology and therapy · 2023Review
- Improving Yields in Multi-analyte Extractions by Utilizing Post-homogenized Tissue Debris.The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society · 2023Article
- meth-SemiCancer: a cancer subtype classification framework via semi-supervised learning utilizing DNA methylation profiles.BMC bioinformatics · 2023Article
- Pan-cancer genomic analysis shows hemizygous PTEN loss tumors are associated with immune evasion and poor outcome.Scientific reports · 2023Article
- CAR T Cell Therapy: A Versatile Living Drug.International journal of molecular sciences · 2023Review
- Fragment length profiles of cancer mutations enhance detection of circulating tumor DNA in patients with early-stage hepatocellular carcinoma.BMC cancer · 2023Article
- From the Catastrophic Objective Irreproducibility of Cancer Research and Unavoidable Failures of Molecular Targeted Therapies to the Sparkling Hope of Supramolecular Targeted Strategies.International journal of molecular sciences · 2023Review
- Tumor heterogeneity: preclinical models, emerging technologies, and future applications.Frontiers in oncology · 2023Review
- The prognostic value ofCancer imaging : the official publication of the International Cancer Imaging Society · 2022Article
- HCV and tumor-initiating stem-like cells.Frontiers in physiology · 2022Review
- Current Status of the Use of Multifunctional Enzymes as Anti-Cancer Drug Targets.Pharmaceutics · 2021Review
- Residue substitution enhances the immunogenicity of neoepitopes from gastric cancers.Cancer biology & medicine · 2021Article
51 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Cancer recapitulates Darwinian evolution. Mutations acquired during life that provide cells with a growth or survival advantage will preferentially multiply to form a tumor. As a result of The Cancer Genome Atlas Project, we have gathered detailed information on the nucleotide sequence changes in a number of human cancers. The sources of mutations in cancer are diverse, and the complexity of those found to be clonally present in tumors has increasingly made it difficult to identify key rate-limiting genes for tumor growth that could serve as potential targets for directed therapies. The impact of DNA sequencing on future cancer research and personalized therapy is likely to be profound and merits critical evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.